James Ellars Official

There’s a lot to unpack from the past few days. Congress made a major move on immigration enforcement, scientists delivered genuinely exciting news in the fight against one of the most feared cancers, and a California election reminded us that political careers can surprise you. Let’s walk through it together.

Congress Voted on $70 Billion for Immigration Enforcement

Early Friday morning, after an all-night session in the Senate, lawmakers passed a $70 billion bill to fund Immigration and Customs Enforcement and the Border Patrol for the next three years. The vote was 52–47, mostly along party lines. The bill covers the agencies doing day-to-day enforcement work — processing, detention, and border operations.

The bill also included something that drew a lot of concern from both parties: a large settlement fund that critics, including some Republicans, called a potential slush fund with no clear limits on how it can be spent. Sen. Lisa Murkowski of Alaska was the only Republican to vote against the whole package. The bill now heads to the House, where more debate is expected. Whatever your views on immigration policy, it’s worth knowing what your tax dollars are being directed toward — and asking your representatives the hard questions about the parts of this bill that weren’t debated as openly as they should have been.

A New Drug Is Changing the Story for Pancreatic Cancer Patients

Here’s some news that deserves more attention than it’s gotten. A drug called daraxonrasib, developed by a company called Revolution Medicines, nearly doubled survival time for patients with advanced pancreatic cancer in a major clinical trial. We’re talking about median survival going from 6.7 months on standard chemotherapy to 13.2 months on the new drug. When researchers presented these findings at the American Society of Clinical Oncology meeting in Chicago last week, the normally reserved audience of doctors and scientists gave them a standing ovation.

For the roughly 60,000 Americans diagnosed with pancreatic cancer each year, this kind of result is deeply meaningful. The disease has long been one of the hardest to treat, often diagnosed too late. The FDA has already granted daraxonrasib a Breakthrough Therapy designation, which helps speed up the review process. It’s available now through expanded access for patients who have already gone through chemotherapy. If you or someone you love has been touched by this disease, it may be worth asking an oncologist about this development.

In California, a Political Comeback Worth Noticing

California held its primary election for governor last week, and the results were surprising. Xavier Becerra, who served as Health and Human Services Secretary in the Biden administration, has claimed the top spot heading into November. Just two months ago, he was polling in single digits. His rise came after another candidate’s campaign collapsed under serious allegations, and Becerra steadily gained support from voters looking for experience and steadiness.

The second spot in California’s top-two primary is still being counted, with Republican Steve Hilton and Democrat Tom Steyer running close. We’ll know more in the coming days. But regardless of party, it’s a good reminder that elections can shift quickly — and that showing up and paying attention always matters.